1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,880 | 3,000 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2026 FIRST QUARTERLY REPORT | - | HKEx | ||
| Mo | JUNSHI BIO (01877): PROPOSED ADOPTION OF THE 2026 A SHARE EMPLOYEE STOCK OWNERSHIP SCHEME | 1 | HKEx | ||
| Mo | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESOLUTIONS OF THE NINETEENTH MEETING ... | - | HKEx | ||
| Mo | JUNSHI BIO (01877): 2025 ANNUAL REPORT | - | HKEx | ||
| 23.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PLAN FOR THE REDUCTION IN THE SHAREHOLDING ... | 1 | HKEx | ||
| 21.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE ADDITION OF IMPLEMENTING ENTITY OF CERTAIN ... | - | HKEx | ||
| 20.04. | Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026 | 402 | GlobeNewswire (Europe) | SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 15.04. | JUNSHI BIO (01877): DATE OF BOARD MEETING | - | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 10.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE EXPIRATION OF THE PLAN FOR THE REDUCTION ... | 1 | HKEx | ||
| 31.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESULTS OF THE SHAREHOLDING INCREASE ... | - | HKEx | ||
| 20.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2025 ANNUAL RESULTS ... | 1 | HKEx | ||
| 16.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* VOLUNTARY ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 13.03. | Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates | 449 | GlobeNewswire (Europe) | SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to... ► Artikel lesen | |
| 13.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT | 1 | HKEx | ||
| 13.03. | JUNSHI BIO (01877): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | 2 | HKEx | ||
| 13.03. | JUNSHI BIO (01877): ADJUSTMENT OF THE STRATEGIC COMMITTEE TO THE STRATEGIC AND ESG COMMITTEE; AMENDMENTS TO AND FORMULATION OF CERTAIN INTERNAL MANAGEMENT ... | 3 | HKEx | ||
| 13.03. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE STRATEGIC AND ESG COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 13.03. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 13.03. | JUNSHI BIO (01877): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 12.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RETURN OF IDLE PROCEEDS USED FOR TEMPORARY ... | - | HKEx |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| OCUGEN | 1,468 | -0,68 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,600 | -3,58 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INFLARX | 1,790 | +1,24 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | -1,95 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| SAREPTA THERAPEUTICS | 17,960 | +0,90 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,152 | -0,86 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 57,10 | -3,87 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 61,20 | -2,27 % | JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating | ||
| TELIX PHARMACEUTICALS | 9,300 | -0,90 % | Telix Pharmaceuticals Limited: TLX101-Px (Pixlumi) MAA Accepted in Europe | MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,757 | -1,05 % | EQS-Media: Attraktive Chance-Risiko-Konstellation? Onco-Innovations gibt erfolgreiches Scale-up bekannt | EQS-Media / 29.04.2026 / 12:18 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gab unter Bezugnahme auf seine Pressemitteilung vom 21. April 2026... ► Artikel lesen | |
| TWIST BIOSCIENCE | 51,22 | +2,95 % | Twist Bioscience Q2 2026 Earnings Preview | ||
| REPLIGEN | 96,98 | -3,79 % | Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1 | ||
| UNIQURE | 16,640 | -2,12 % | uniQure Inc.: uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease | ~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~
~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential... ► Artikel lesen | |
| PHARMAMAR | 96,45 | +0,36 % | PHARMA MAR, S.A.: The Company files first quarter 2026 financial information. |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,180 (+6,72 %) liegt der Kurs bei 2,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.